Site Expansion - Regional Round-Up: Maryland
Regional Round-Up: Maryland
Population
5,458,137
Workforce
2,914,323
Unemployment rate
4.1%
Key cities and populations
Primary Metropolitan Statistical Areas:
Baltimore: 2,552,994;
Washington, DC-Maryland-Virginia-West Virginia: 4,923,153
Targeted industries
Very strong genomics, proteomics, drug discovery and biodefense industries; continued commitment to promoting R&D, biomanufacturing, and pharmaceutical presence; new emphasis on agricultural biotechnology as well as industrial and environmental bioapplications
Biopharm employment
More than 80,000 (half in private sector, half in government research/academia)
Academia and government affiliated with biopharm industry
National Institutes of Health
The Johns Hopkins University; University System of Maryland
US Army Medical Research Institute of Infectious Diseases, Fort Detrick
Edgewood Army Chemical and Biological Defense Command
Walter Reed Army Institute of Research
FDA
USDA
Primary business strengths
3rd largest US industry cluster; highest US concentration of bioscience educated workforce; competitive cost savings on East Coast operations; easy access to rail and air transportation; low personal income tax rate; low corporate income tax structure
Tax and other incentives
Multiple programs individually tailored to each business
BioClusters
Most of Marylands bioscience industry lies within a 30 mile (50 km) radius between the cities of Washington, DC, Frederick, MD, and Baltimore, MD; approximately two-thirds of this community is in Marylands Washington suburbs, and one-third is in the greater-Baltimore area
Future plans for biopharm growth
Baltimores growth is centered around two biotechnology park initiatives, one in East Baltimore near Johns Hopkins Hospital and the other at the University of Maryland-Baltimore
Expanding the number of biotech incubator facilities (already the highest in the US)
Recent research facility expansions in Montgomery County
State committment to biopharm industry growth
Specialized State industry-focus team in DBED for business development, strategic partnering, and financial investment services to outstanding companies.
Long-term State investments in R&D, biomanufacturing, BSL3 facilities, incubators, and a five-center UMD Biotechnology Institute
State-level contacts
MD Department of Business and Economic Development:
Regional-level contacts
MdBio, Inc., 301.228.2445:
C. Robert Eaton, president,
Articles in this issue
Editorial—BioPharm Reflects the Industry
Site Expansion - Regional Round-Up: Virginia
Qualification of Raw Materials for Biopharmaceutical Use
Outsourcing Report: Big Pharma Promises to Focus on Productivity
Costing Issues in the Production of Biopharmaceuticals
Canada: On the Biopharmaceutical Fast Track
Looking for Clues to a Sustained Biopharm Resurgence? Check Out the Job Picture
The State of Intellectual Property in Canada: Pending and Spending
Site Expansion - Regional Round-Up: Maryland
Regulatory Beat: Electronic Information Systems Promote Drug Development, Patient Safety
Related Content
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024Podcast
The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
